OncoSec to Attend 30th Annual JP Morgan Healthcare Conference and Present at Investor Conferences in San Francisco

SAN DIEGO, CA, January 5, 2012 — OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage Oncology Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that representatives of OncoSec’s executive management team will be attending the 30th Annual JP Morgan Healthcare Conference in San Francisco, January 9-11. In addition, Punit Dhillon, President and CEO, will be presenting a company update at two investor conferences held concurrently with the JP Morgan Conference.

30th Annual JP Morgan Global Healthcare Conference
The Westin St. Francis
335 Powell Street
San Francisco, CA
January 9-12, 2012

Sir Francis Drake Hotel
450 Powell Street
San Francisco, CA 94102
January 9-12, 2012

OncoSec Presentation
January 10, 2012
11:45AM PT

BioTech Showcase
Parc 55 Wyndham
55 Cyril Magnin Street
San Francisco, CA 94102
January 9-11, 2012

OncoSec Presentation
January 11, 2012
4:00PM PT

Live and archived webcast will be accessible on OncoSec’s website www.oncosec.com please allow 15 minutes prior to the beginning of the presentation to allow for any software downloads.

To arrange a meeting with management please contact Adam Holdsworth,
The Investor Relations Group 212-285-3210 aholdsworth@investorrelationsgroup.com

The prestigious JP Morgan Global Healthcare Conference is one of the world’s largest premier life sciences oriented conference that attracts thousands of healthcare and life science business executives, established industry thought leaders, emerging companies, innovative technology creators and financiers worldwide to San Francisco.

OneMedForum, currently in its 5th year provides an efficient means for industry business and investment professionals to meet managing executives of emerging and rapid growth life science companies who are shaping the changing future of healthcare. The forum will offer presentations from companies of various life science facets, panels and workshops to provide attendees with strategic and practical insight.

Currently in its 4th year, BioTech Showcase will feature presentations by over 200 public and private life science companies to an audience of both public and private investors, business development executives and professional advisors who are interested in creating potential investment opportunities and collaborations.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.